Integra LifeSciences Holdings Corporation (IART) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$14.00
Price Target
$12.00
Target Range
$12.00 — $12.00
Analyst Rating
Buy
Forward P/E6.0x
Trailing P/E-2.1x
Forward PEG—
Implied Growth+136.4%
Median Target$12.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$12
-14.3%
Consensus
$12
-14.3%
Bull Case
$12
-14.3%
IART Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Integra LifeSciences Holdings Corporation (IART) has a Wall Street consensus price target of $12.00, based on estimates from 26 covering analysts. With the stock currently trading at $14.00, this represents a potential downside of -14.3%. The company has a market capitalization of $1.09B.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 5 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IART trades at a trailing P/E of -2.1x and forward P/E of 6.0x. Analysts expect EPS to grow +136.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+47.8%
Avg Forward P/E84.4x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
 ATRCAtriCure, Inc. | $1.4B | $28.01 | $50.67 | +80.9% | Buy | 373.5x | 19 |
 NTRANatera, Inc. | $29.6B | $215.09 | $262.50 | +22.0% | Buy | — | 27 |
 MMSIMerit Medical Systems, Inc. | $3.7B | $61.63 | $95.00 | +54.1% | Buy | 15.3x | 13 |
 LMATLeMaitre Vascular, Inc. | $2.5B | $110.22 | $101.50 | -7.9% | Buy | 38.0x | 20 |
 GMEDGlobus Medical, Inc. | $12.1B | $89.22 | $110.67 | +24.0% | Buy | 20.0x | 36 |
 AORTArtivion, Inc. | $1.7B | $34.70 | $52.00 | +49.9% | Buy | 96.8x | 12 |
 TMDXTransMedics Group, Inc. | $2.5B | $72.92 | $144.75 | +98.5% | Buy | 29.9x | 12 |
 ANGOAngioDynamics, Inc. | $459M | $11.05 | $16.50 | +49.3% | Hold | — | 11 |
Upside Potential Comparison
NVCRTMDXATRCMMSIAORTANGOGMEDNTRASee IART's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IART Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IART vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIART — Frequently Asked Questions
Quick answers to the most common questions about buying IART stock.
What is the IART stock price target for 2026?
IART's consensus price target is $12, -14.3% below the current price of $14. The 26 analysts tracking IART see downside risk at present valuations.
Is IART a buy, sell, or hold?
IART has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is mixed, with 10 Hold ratings making up the largest segment. The consensus 12-month price target of $12 implies -14.3% downside from current levels.
Is IART stock overvalued or undervalued?
With a forward P/E of 5.962x, IART trades at a relatively low valuation. The consensus target of $12 implies -14.3% move, suggesting the market may be pricing in risks.
How high can IART stock go?
The most bullish Wall Street analyst has a price target of $12 for IART, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover IART stock?
IART is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 10 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the IART stock forecast?
The 12-month IART stock forecast based on 26 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
What is IART's forward P/E ratio?
IART trades at a forward P/E ratio of 6.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy IART stock?
Analysts are cautious on IART, with 5 Sell ratings and a price target of $12 (-14.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do IART price targets vary so much?
IART analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.